Septerna (SEPN) Non-Current Deffered Revenue (2025 - 2026)
Septerna (SEPN) posted quarterly Non-Current Deffered Revenue of $92.2 million for Q1 2026, down 12.97% quarter-over-quarter from $105.9 million in Q4 2025.
Septerna (SEPN) Non-Current Deffered Revenue (2025 - 2026) Analysis & Trends
Septerna's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $92.2 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $92.2 million; the TTM figure through Mar 2026 stood at $92.2 million (changed N/A YoY), while the FY2025 annual figure was $105.9 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $92.2 million, down from $105.9 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $120.6 million in Q3 2025, with the low at $92.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 80.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.04 Mn |
| Mar 31, 2026 | 92.18 Mn |
| Dec 31, 2025 | 105.92 Mn |
| Sep 30, 2025 | 120.65 Mn |